2186:HKEXLuye Pharma Group Ltd. Analysis

Sobal Corporation is trading at ¥900, just above its calculated support of ¥896 and well below the DCF fair value of ¥1,179, indicating a material discount. The 20‑day and 50‑day SMAs (¥900.55 and ¥903.04) sit above the current price, and the MACD histogram is negative, signaling short‑term bearish momentum. RSI sits near 49, suggesting no immediate overbought pressure, while volume is on a decreasing trend, hinting at waning buying interest. Despite the technical softness, the company posts a healthy 9.3% revenue growth, a 5.1% net margin and generates ¥279.8 M of free cash flow, backed by ¥3.8 B of cash and zero debt. The dividend yield of 3.68% with a 56% payout ratio appears sustainable given the strong cash position. Relative to the technology‑software sector, the stock’s beta of 0.05 and 30‑day volatility of 5% point to low market‑price sensitivity. Overall, the valuation gap, solid fundamentals and attractive dividend make the stock a compelling value play, while the near‑term price action remains constrained by bearish technical signals.